Latest news for Icade (OTC:CDMGF) Stock

Icade is a French real estate investment trust involved in the ownership and management of commercial property around Paris. The vast majority of Icade's real estate portfolio is split between office and business park properties. Nearly all of these are located in Greater Paris with roughly half residing in the inner and outer rings of the metro area. Icade derives Majority of its revenue from its Property Development division through the sale of real estate. Rental income from short- to mid-term leases out of its Property Investment division also represents a substantial revenue stream. Institutional investors, private investors, and buyers represent fairly equal parts of the company's customer orders. Icade also has holdings in healthcare properties outside of the Paris region.

News

Intraday Update

Markets

Movers

Trading Ideas

ACEJF

AFGC

AGFMF

AGRX

AGYS

ALAC

AMRC

ANCTF

APMCF

APPF

APYRF

ATRC

BBSRF

BRLXF

CDMGF

CGEN

CGJTF

CGMLF

CSBTF

CTRN

CWCO

CWST

CYDY

CZFS

DCMYY

DEAC

DNKLY

EDPFY

ELVT

EPAY

EPRT

ESINQ

EVRG

EXPO

FCPT

FJTSF

FLXT

GABC

GBBT

GRBK

GSAH

GVDNY

HAPP

HMSVF

HSSHF

HTLF

IESC

IHRT

KNBIF

KNSL

KYOCY

LAUR

LEN-B

MCQEF

MGEE

MINI

MITEY

Blackrock Muni New York Intermediate Duration Fu

Blackrock Muniholdings California Quality Fund

NDAQ

NDSN

Nuveen Insured California Tax-Free Advantage Municipal Fund

Nuveen New Jersey Dividend Advantage Municipal Fund

OBCI

Stocks That Hit 52-Week Highs On Tuesday

Icade

Gecina Offers A Sustainable Dividend Yield Of 5.3%

Icade: Outperformance From The Second French REIT

Icade reports IFRS group revenue at nearly €699M

Icade 2024 Q2 - Results - Earnings Call Presentation

Icade (CDMGF) Q2 2024 Earnings Call Transcript

Icade: Don't Be Fooled By Its 24% Dividend Yield

Gecina: Positive Operating Performance In H1 2024 Supported Its High-Dividend Yield

Icade 2024 Q3 - Results - Earnings Call Presentation

Icade (CDMGF) Q3 2024 Earnings Call Transcript

Icade reports results as of Sep. 30

EQIX

GECFF

UNBLF

&nbsp;

<h2>Upgrades</h2>

<ul>
	<li>Barrington Research upgraded the previous rating for Dentsply Sirona Inc (NASDAQ:<a class="ticker" href="/stock/XRAY#NASDAQ">XRAY</a>) from Market Perform to Outperform. Dentsply Sirona earned $0.87 in the fourth quarter, compared to $0.73 in the year-ago quarter. The stock has a 52-week-high of $60.78 and a 52-week-low of $31.57. At the end of the last trading period, Dentsply Sirona closed at $59.71.</li>
	<li>BTIG upgraded the previous rating for TrueCar Inc (NASDAQ:<a class="ticker" href="/stock/TRUE#NASDAQ">TRUE</a>) from Neutral to Buy. For the fourth quarter, TrueCar had an EPS of $0.01, compared to year-ago quarter EPS of $0.01. At the moment, the stock has a 52-week-high of $6.47 and a 52-week-low of $1.98. TrueCar closed at $5.18 at the end of the last trading period.</li>
	<li>For Zoom Video Communications Inc (NASDAQ:<a class="ticker" href="/stock/ZM#NASDAQ">ZM</a>), Piper Sandler upgraded the previous rating of Neutral to Overweight. For the fourth quarter, Zoom Video Communications had an EPS of $1.22, compared to year-ago quarter EPS of $0.15. At the moment, the stock has a 52-week-high of $588.84 and a 52-week-low of $97.37. Zoom Video Communications closed at $409.66 at the end of the last trading period.</li>
	<li>CIBC upgraded the previous rating for Bank of Nova Scotia (NYSE:<a class="ticker" href="/stock/BNS#NYSE">BNS</a>) from Neutral to Outperformer. In the first quarter, Bank of Nova Scotia showed an EPS of $1.44, compared to $1.41 from the year-ago quarter. The stock has a 52-week-high of $61.35 and a 52-week-low of $31.94. At the end of the last trading period, Bank of Nova Scotia closed at $59.74.</li>
	<li>According to BMO Capital, the prior rating for Extra Space Storage Inc (NYSE:<a class="ticker" href="/stock/EXR#NYSE">EXR</a>) was changed from Market Perform to Outperform. In the fourth quarter, Extra Space Storage showed an EPS of $1.48, compared to $1.27 from the year-ago quarter. The stock has a 52-week-high of $131.59 and a 52-week-low of $72.70. At the end of the last trading period, Extra Space Storage closed at $123.67.</li>
	<li>Exane BNP Paribas upgraded the previous rating for Tenaris SA (NYSE:<a class="ticker" href="/stock/TS#NYSE">TS</a>) from Underperform to Neutral. Tenaris earned $0.18 in the fourth quarter, compared to $0.26 in the year-ago quarter. The current stock performance of Tenaris shows a 52-week-high of $21.97 and a 52-week-low of $8.86. Moreover, at the end of the last trading period, the closing price was at $21.55.</li>
	<li>For Satsuma Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="/stock/STSA#NASDAQ">STSA</a>), Credit Suisse upgraded the previous rating of Underperform to Neutral. Satsuma Pharmaceuticals earned $0.69 in the third quarter, compared to $2.26 in the year-ago quarter. The stock has a 52-week-high of $36.10 and a 52-week-low of $3.50. At the end of the last trading period, Satsuma Pharmaceuticals closed at $6.51.</li>
	<li>For Repay Holdings Corp (NASDAQ:<a class="ticker" href="/stock/RPAY#NASDAQ">RPAY</a>), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. Repay Holdings earned $0.17 in the fourth quarter, compared to $0.20 in the year-ago quarter. The current stock performance of Repay Holdings shows a 52-week-high of $28.42 and a 52-week-low of $10.69. Moreover, at the end of the last trading period, the closing price was at $22.63.</li>
	<li>According to KeyBanc, the prior rating for Akamai Technologies Inc (NASDAQ:<a class="ticker" href="/stock/AKAM#NASDAQ">AKAM</a>) was changed from Sector Weight to Overweight. In the fourth quarter, Akamai Technologies showed an EPS of $1.33, compared to $1.23 from the year-ago quarter. At the moment, the stock has a 52-week-high of $124.91 and a 52-week-low of $75.18. Akamai Technologies closed at $95.94 at the end of the last trading period.</li>
</ul>

<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>

&nbsp;

<h2>Downgrades</h2>

<ul>
	<li>According to Wedbush, the prior rating for Skyline Champion Corp (NYSE:<a class="ticker" href="/stock/SKY#NYSE">SKY</a>) was changed from Outperform to Neutral. In the third quarter, Skyline Champion showed an EPS of $0.38, compared to $0.32 from the year-ago quarter. The stock has a 52-week-high of $47.57 and a 52-week-low of $10.82. At the end of the last trading period, Skyline Champion closed at $46.86.</li>
	<li>For ADT Inc (NYSE:<a class="ticker" href="/stock/ADT#NYSE">ADT</a>), Barclays downgraded the previous rating of Equal-Weight to Underweight. ADT earned $0.12 in the fourth quarter, compared to $0.03 in the year-ago quarter. The current stock performance of ADT shows a 52-week-high of $17.21 and a 52-week-low of $3.40. Moreover, at the end of the last trading period, the closing price was at $7.73.</li>
	<li>For Inseego Corp (NASDAQ:<a class="ticker" href="/stock/INSG#NASDAQ">INSG</a>), Stifel downgraded the previous rating of Buy to Hold. In the fourth quarter, Inseego showed an EPS of $0.07, compared to $0.10 from the year-ago quarter. The stock has a 52-week-high of $21.93 and a 52-week-low of $3.91. At the end of the last trading period, Inseego closed at $15.03.</li>
	<li>According to Raymond James, the prior rating for Switch Inc (NYSE:<a class="ticker" href="/stock/SWCH#NYSE">SWCH</a>) was changed from Strong Buy to Outperform. In the fourth quarter, Switch showed an EPS of $0.06, compared to $0.04 from the year-ago quarter. The current stock performance of Switch shows a 52-week-high of $19.99 and a 52-week-low of $10.30. Moreover, at the end of the last trading period, the closing price was at $17.69.</li>
	<li>According to Needham, the prior rating for Applied Optoelectronics Inc (NASDAQ:<a class="ticker" href="/stock/AAOI#NASDAQ">AAOI</a>) was changed from Buy to Hold. Applied Optoelectronics earned $0.20 in the fourth quarter, compared to $0.18 in the year-ago quarter. At the moment, the stock has a 52-week-high of $17.57 and a 52-week-low of $5.00. Applied Optoelectronics closed at $9.02 at the end of the last trading period.</li>
	<li>For Athenex Inc (NASDAQ:<a class="ticker" href="/stock/ATNX#NASDAQ">ATNX</a>), Truist Securities downgraded the previous rating of Buy to Hold. In the fourth quarter, Athenex showed an EPS of $0.53, compared to $0.28 from the year-ago quarter. At the moment, the stock has a 52-week-high of $15.24 and a 52-week-low of $5.24. Athenex closed at $5.46 at the end of the last trading period.</li>
	<li>According to Jefferies, the prior rating for FibroGen Inc (NASDAQ:<a class="ticker" href="/stock/FGEN#NASDAQ">FGEN</a>) was changed from Buy to Hold. For the fourth quarter, FibroGen had an EPS of $0.64, compared to year-ago quarter EPS of $1.12. At the moment, the stock has a 52-week-high of $57.21 and a 52-week-low of $22.65. FibroGen closed at $50.53 at the end of the last trading period.</li>
	<li>For Viatris Inc (NASDAQ:<a class="ticker" href="/stock/VTRS#NASDAQ">VTRS</a>), JP Morgan downgraded the previous rating of Overweight to Neutral. The current stock performance of Viatris shows a 52-week-high of $18.86 and a 52-week-low of $14.56. Moreover, at the end of the last trading period, the closing price was at $14.72.</li>
	<li>JP Morgan downgraded the previous rating for Athenex Inc (NASDAQ:<a class="ticker" href="/stock/ATNX#NASDAQ">ATNX</a>) from Overweight to Neutral. For the fourth quarter, Athenex had an EPS of $0.53, compared to year-ago quarter EPS of $0.28. The current stock performance of Athenex shows a 52-week-high of $15.24 and a 52-week-low of $5.24. Moreover, at the end of the last trading period, the closing price was at $5.46.</li>
</ul>

<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>

<h2>Initiations</h2>

<ul>
	<li>For Lucira Health Inc (NASDAQ:<a class="ticker" href="/stock/LHDX#NASDAQ">LHDX</a>), William Blair initiated coverage, by setting the current rating at Outperform. The stock has a 52-week-high of $37.98 and a 52-week-low of $18.27. At the end of the last trading period, Lucira Health closed at $19.39.</li>
	<li>Stifel initiated coverage on Angion Biomedica Corp (NASDAQ:<a class="ticker" href="/stock/ANGN#NASDAQ">ANGN</a>) with a Buy rating. The price target for Angion Biomedica is set to $40.00. The stock has a 52-week-high of $26.30 and a 52-week-low of $16.00. At the end of the last trading period, Angion Biomedica closed at $19.92.</li>
	<li>Benchmark initiated coverage on Clene Inc (NASDAQ:<a class="ticker" href="/stock/CLNN#NASDAQ">CLNN</a>) with a Buy rating. The price target for Clene is set to $25.00. The stock has a 52-week-high of $16.50 and a 52-week-low of $6.23. At the end of the last trading period, Clene closed at $13.58.</li>
	<li>Guggenheim initiated coverage on Bolt Biotherapeutics Inc (NASDAQ:<a class="ticker" href="/stock/BOLT#NASDAQ">BOLT</a>) with a Buy rating. The price target for Bolt Biotherapeutics is set to $42.00. The stock has a 52-week-high of $35.88 and a 52-week-low of $22.63. At the end of the last trading period, Bolt Biotherapeutics closed at $30.00.</li>
	<li>Morgan Stanley initiated coverage on MP Materials Corp (NYSE:<a class="ticker" href="/stock/MP#NYSE">MP</a>) with an Overweight rating. The price target for MP Materials is set to $57.00. At the moment, the stock has a 52-week-high of $49.43 and a 52-week-low of $15.45. MP Materials closed at $46.37 at the end of the last trading period.</li>
	<li>With an Overweight rating, Morgan Stanley initiated coverage on Bolt Biotherapeutics Inc (NASDAQ:<a class="ticker" href="/stock/BOLT#NASDAQ">BOLT</a>). The price target seems to have been set at $45.00 for Bolt Biotherapeutics. The stock has a 52-week-high of $35.88 and a 52-week-low of $22.63. At the end of the last trading period, Bolt Biotherapeutics closed at $30.00.</li>
	<li>With an Outperform rating, SVB Leerink initiated coverage on Pharvaris NV (NASDAQ:<a class="ticker" href="/stock/PHVS#NASDAQ">PHVS</a>). The price target seems to have been set at $50.00 for Pharvaris. The current stock performance of Pharvaris shows a 52-week-high of $42.86 and a 52-week-low of $23.06. Moreover, at the end of the last trading period, the closing price was at $39.23.</li>
	<li>With a Neutral rating, Goldman Sachs initiated coverage on Immunocore Holdings PLC (NASDAQ:<a class="ticker" href="/stock/IMCR#NASDAQ">IMCR</a>). The price target seems to have been set at $40.00 for Immunocore Holdings. The current stock performance of Immunocore Holdings shows a 52-week-high of $61.99 and a 52-week-low of $39.02. Moreover, at the end of the last trading period, the closing price was at $49.05.</li>
	<li>With an Overweight rating, Piper Sandler initiated coverage on AVITA Medical Inc (NASDAQ:<a class="ticker" href="/stock/RCEL#NASDAQ">RCEL</a>). The price target seems to have been set at $27.00 for AVITA Medical. AVITA Medical earned $0.26 in the second quarter. The current stock performance of AVITA Medical shows a 52-week-high of $30.78 and a 52-week-low of $4.00. Moreover, at the end of the last trading period, the closing price was at $21.49.</li>
</ul>

<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Upgrades

Downgrades

Initiation

Analyst Ratings

AAOI

AKAM

ANGN

ATNX

BHCCF

BOLT

CLNN

CRPLF

FGEN

HOYFF

IMCR

INSG

KBCSY

KRYAY

LHDX

PHVS

RCEL

REMYY

RPAY

STSA

STWRY

SWCH

THNPF

TMSNY

TRUE

VTRS

XRAY

Benzinga's Top Ratings Upgrades, Downgrades For March 2, 2021

Morgan Stanley upgrades Icade (OTC:<a class="ticker" href="/stock/CDMGF#OTC">CDMGF</a>) from Equal-Weight to Overweight.

Morgan Stanley Upgrades Icade to Overweight

Comments

Icade

News

Latest news for Icade (OTC:CDMGF) Stock

Tuesday, March 02, 2021

Tuesday, January 28, 2020

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga